Cargando…

N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions

Background: N6 adenosine methylation (m6A) is the most abundant internal RNA modification in eukaryotic cells. Dysregulation of m6A has been associated with the perturbations of cell proliferation and cell death in different diseases. However, the roles of m6A in the neurodegenerative process and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Bingying, Zhang, Yanbo, Liang, Meng, Du, Zengkan, Li, Haibo, Fan, Cunxiu, Zhang, Hailing, Jiang, Yan, Bi, Xiaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436914/
https://www.ncbi.nlm.nih.gov/pubmed/34461609
http://dx.doi.org/10.18632/aging.203457
_version_ 1783752073305653248
author Du, Bingying
Zhang, Yanbo
Liang, Meng
Du, Zengkan
Li, Haibo
Fan, Cunxiu
Zhang, Hailing
Jiang, Yan
Bi, Xiaoying
author_facet Du, Bingying
Zhang, Yanbo
Liang, Meng
Du, Zengkan
Li, Haibo
Fan, Cunxiu
Zhang, Hailing
Jiang, Yan
Bi, Xiaoying
author_sort Du, Bingying
collection PubMed
description Background: N6 adenosine methylation (m6A) is the most abundant internal RNA modification in eukaryotic cells. Dysregulation of m6A has been associated with the perturbations of cell proliferation and cell death in different diseases. However, the roles of m6A in the neurodegenerative process and cognitive dysfunction are unclear. Methods: We systematically investigated the molecular alterations of m6A regulators and their clinical relevance with cognitive dysfunctions using published datasets of Alzheimer's Disease (AD), vascular dementia, and mild cognitive impairment (MCI). Findings: The expressions of m6A regulators vary in different tissues and closely correlate with neurodegenerative pathways. We identified co-expressive m6A regulators SNRPG and SNRPD2 as potential biomarkers to predict transformation from MCI to AD. Moreover, we explored correlations between Apolipoprotein E4 and m6A methylations. Interpretation: Collectively, these findings suggest that m6A methylations as potential biomarkers and therapeutic targets for cognitive dysfunction. Funding: This work was supported by the National Natural Science Foundation of China (81871040) and the Shanghai Health System Talent Training Program (2018BR29).
format Online
Article
Text
id pubmed-8436914
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-84369142021-09-14 N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions Du, Bingying Zhang, Yanbo Liang, Meng Du, Zengkan Li, Haibo Fan, Cunxiu Zhang, Hailing Jiang, Yan Bi, Xiaoying Aging (Albany NY) Research Paper Background: N6 adenosine methylation (m6A) is the most abundant internal RNA modification in eukaryotic cells. Dysregulation of m6A has been associated with the perturbations of cell proliferation and cell death in different diseases. However, the roles of m6A in the neurodegenerative process and cognitive dysfunction are unclear. Methods: We systematically investigated the molecular alterations of m6A regulators and their clinical relevance with cognitive dysfunctions using published datasets of Alzheimer's Disease (AD), vascular dementia, and mild cognitive impairment (MCI). Findings: The expressions of m6A regulators vary in different tissues and closely correlate with neurodegenerative pathways. We identified co-expressive m6A regulators SNRPG and SNRPD2 as potential biomarkers to predict transformation from MCI to AD. Moreover, we explored correlations between Apolipoprotein E4 and m6A methylations. Interpretation: Collectively, these findings suggest that m6A methylations as potential biomarkers and therapeutic targets for cognitive dysfunction. Funding: This work was supported by the National Natural Science Foundation of China (81871040) and the Shanghai Health System Talent Training Program (2018BR29). Impact Journals 2021-08-30 /pmc/articles/PMC8436914/ /pubmed/34461609 http://dx.doi.org/10.18632/aging.203457 Text en Copyright: © 2021 Du et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Du, Bingying
Zhang, Yanbo
Liang, Meng
Du, Zengkan
Li, Haibo
Fan, Cunxiu
Zhang, Hailing
Jiang, Yan
Bi, Xiaoying
N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions
title N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions
title_full N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions
title_fullStr N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions
title_full_unstemmed N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions
title_short N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions
title_sort n6-methyladenosine (m6a) modification and its clinical relevance in cognitive dysfunctions
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436914/
https://www.ncbi.nlm.nih.gov/pubmed/34461609
http://dx.doi.org/10.18632/aging.203457
work_keys_str_mv AT dubingying n6methyladenosinem6amodificationanditsclinicalrelevanceincognitivedysfunctions
AT zhangyanbo n6methyladenosinem6amodificationanditsclinicalrelevanceincognitivedysfunctions
AT liangmeng n6methyladenosinem6amodificationanditsclinicalrelevanceincognitivedysfunctions
AT duzengkan n6methyladenosinem6amodificationanditsclinicalrelevanceincognitivedysfunctions
AT lihaibo n6methyladenosinem6amodificationanditsclinicalrelevanceincognitivedysfunctions
AT fancunxiu n6methyladenosinem6amodificationanditsclinicalrelevanceincognitivedysfunctions
AT zhanghailing n6methyladenosinem6amodificationanditsclinicalrelevanceincognitivedysfunctions
AT jiangyan n6methyladenosinem6amodificationanditsclinicalrelevanceincognitivedysfunctions
AT bixiaoying n6methyladenosinem6amodificationanditsclinicalrelevanceincognitivedysfunctions